• Home
  • About IMWG
    • Mission
    • History
  • Publications
  • Summaries
  • Events
    • Annual Summit
    • Robert A. Kyle Lifetime Achievement Award
  • Multimedia
    • Conference Series
    • Photo Gallery
  • Home
  • About IMWG
    • Mission
    • History
  • Publications
  • Summaries
  • Events
    • Annual Summit
    • Robert A. Kyle Lifetime Achievement Award
  • Multimedia
    • Conference Series
      • ASH 2018 – San Diego
      • Stockholm 2018
      • ASH 2017 – Atlanta, GA
      • Madrid 2017
      • ASH 2016
      • Copenhagen 2016
      • ASH 2015
      • Vienna 2015
      • ASH 2014
      • Milan 2014
    • Photo Gallery

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib

By imwgimf On January 26, 2012 · Add Comment · In IMWG Publications, Relapse
Promising new drugs are being evaluated for treatment of multiple myeloma (MM), but their impact should be measured against the expected outcome in patients failing current therapies. However, the natural history of relapsed disease in the current era remains unclear. We studied 286 patients with relapsed MM, who were refractory to bortezomib and were relapsed following, refractory to or ineligible to receive, an IMiD (immunomodulatory drug), had measurable disease, and ECOG PS of 0, 1 or 2. The date patients satisfied the entry criteria was defined as time zero (T(0)). The median age at diagnosis was 58 years, and time from diagnosis to T(0) was 3.3 years. Following T(0), 213 […]
Read More »

Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group

By imwgimf On April 15, 2008 · Add Comment · In IMWG Publications, Transplant, Treatment Options
We analyzed the presenting features and survival in 1689 patients with multiple myeloma aged younger than 50 years compared with 8860 patients 50 years of age and older. Of the total 10 549 patients, 7765 received conventional therapy and 2784 received high-dose therapy. Young patients were more frequently male, had more favorable features such as low International Staging System (ISS) and Durie-Salmon stage as well as less frequently adverse prognostic factors including high C-reactive protein (CRP), low hemoglobin, increased serum creatinine, and poor performance status. Survival was significantly longer in young patients (median, 5.2 years vs 3.7 years; P < .001) both after conventional (median, 4.5 years vs 3.3 years; […]
Read More »
 
  • Popular
  • Recent
  • Comments
  • Tags
  • Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaThe updated criteria for the diagnosis of myeloma represent a [...]
  • International Myeloma Working Group (IMWG) Criteria for the Diagnosis of Multiple Myeloma
  • IMWG Guidelines for the Prevention of Thalidomide- and Lenalidomide-Associated Thrombosis in Myeloma
  • Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working GroupWhole Body Low Dose CT (WBLDCT) has important advantages as [...]
  • Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American CountriesLatin American countries (LATAMC) represent a large fraction of patients [...]
  • Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working GroupFor decades conventional skeletal survey (CSS) has been the standard [...]
  • Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG studyIntroduction of new myeloma therapies offers new options for patients [...]
ASCT bone disease bortezomib classification computed tomography consensus cytogenetics diagnosis DVT genetic guidelines IMWG International myeloma working group International Staging System ISS lenalidomide magnetic resonance imaging molecular multiple myeloma myeloma patients prognosis response criteria stem cell survival thalidomide therapy thrombosis transplantation treatment
  • Categories

    • Diagnosis, Staging & Monitoring
    • Guidelines
    • IMWG Publications
    • Maintenance
    • Relapse
    • Supportive Care
    • Transplant
    • Treatment Options
  • Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
    To find out more, including how to control cookies, see here: Cookie Policy
  • Search

 
© 2019 IMWG